slides · global inventory
Source Note
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,355
Current window 76,171-76,200
Pages 3,679
Rows per page 30
Component
76,171-76,200 of 110,355
36
The slide presents specific quantitative targets for FY2024.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations Beat · Guidance1 hit
38
The slide defines Category IV banks as publicly traded US-based banks with assets >$100 billion and <$250 billion in total assets.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
39
Includes a footnote regarding merger-related items.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
40
Includes two distinct tables: one for income/EPS reconciliation and one for allowance coverage ratio.New York Community Bancorp | Results Presentation Deck | 42 slides · New York Community Bancorp
Conference presentation Investor relations 1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
09
The slide uses a structured table to highlight gaps in current treatment standards.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'case study' framework to validate the proposed strategy by drawing a parallel to an existing successful drug (Osimertinib).Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
13
The slide uses a timeline-based customer journey framework to map clinical progression against therapeutic limitations.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
14
The slide uses a matrix-like structure to compare drug generations against clinical outcomes.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations Loop · Mece Breakdown1 hit
17
Includes detailed clinical trial enrollment metrics by dose cohort and patient population.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
18
The slide presents two side-by-side tables detailing patient characteristics and treatment history for the ALKOVE-1 study cohort.Nuvalent | Investor Presentation Deck | 41 slides · Nuvalent
Pitch deck Investor relations 1 hit
05
The slide uses a chronological structure to demonstrate operational momentum.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Solution1 hit
09
The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
10
Uses a 'cite_precedent' framework to validate the strategy by comparing it to the established success of Osimertinib.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
11
The chart visualizes the dominance of Alectinib and Crizotinib in the current market landscape.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Beat · Market SizingLoop · Cost Of Inaction1 hit
13
The slide uses a timeline-based journey map to contrast standard treatments with unmet clinical needs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
14
The slide uses a matrix-style comparison to highlight the superior/differentiated profile of the 4th generation inhibitor NVL-655.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations Loop · Jobs To Be Done1 hit
16
Includes a formula for Selectivity index and a legend for various compound mutations.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
17
The slide provides a detailed breakdown of patient enrollment across different dose cohorts (15mg to 200mg QD) for the NVL-655 clinical trial.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
19
Slide presents two distinct clinical data visualizations: a PK line chart and a waterfall plot for mutation clearance.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
20
Data cut-off: 8 Aug 2023. Includes detailed breakdown of response by mutation type and prior treatment history.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
24
Data cut-off: 8 Aug 2023. N=93 treated patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
25
The slide uses a three-column layout to segment the market by treatment line (3L+, 2L, 1L) and contrast current standards of care with the proposed solution's benefits.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
26
The slide outlines a clinical trial design with specific patient cohorts (2a-2d) and study objectives.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
28
The slide uses a timeline-based framework to contrast 1L and 2L+ treatment landscapes and their associated clinical challenges.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
29
The slide uses a matrix-like comparison to highlight the unique value proposition of NVL-520 compared to standard-of-care drugs.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
34
Includes clinical trial data (ARROS-1 Phase 1) with specific patient subgroup outcomes.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
35
Data as of 13 Sep 2022. N=35 patients.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit
37
Uses a side-by-side comparison framework to contrast 2L+ (salvage) and 1L (front-line) market opportunities.Nuvalent | Investor Presentation Deck | 42 slides · Nuvalent
Pitch deck Investor relations 1 hit